GeneOnline, 177 E COLORADO Boulevard STE 200, Pasadena, CA (2026)

10/14/2026

At BioJapan 2026, held October 7–9 at PACIFICO Yokohama, EirGenix, Inc. presented its dual-engine business model, combining proprietary biosimilar development with contract development and manufacturing organization (CDMO) services.

In an exclusive interview with GeneOnline, Dr. Portia Lin, Senior Vice President and Chief Business Officer at EirGenix, discussed the company’s strategy for strengthening international partnerships, expanding into global markets, and investing in manufacturing technologies.

Japan remains a key market for EirGenix, supported by longstanding pharmaceutical relationships and established commercial manufacturing contracts. While the company continues to expand its business development activities in the United States and Europe, it is also exploring new opportunities with Japanese pharmaceutical companies, biotechnology startups, and academic institutions.

Dr. Lin highlighted the importance of regional partnerships in reaching global markets, explaining that no single company can cover every territory independently. By combining global development strategies with regional licensing and commercialization partners, EirGenix aims to broaden market access while managing development costs.

The company is also planning for future manufacturing demand. With potential capacity expansion by 2030, EirGenix is assessing customer commitments and product demand before making significant capital investments.

Beyond manufacturing capacity, EirGenix is exploring continuous manufacturing, higher-yield production technologies, concentrated formulations, and artificial intelligence to improve productivity and strengthen its technical capabilities.

As Dr. Lin emphasized, companies need their own technical strengths to stand out in an increasingly competitive CDMO market.

10/14/2026

At TAIWAN EXPO USA 2026, held September 24–26 at the Kay Bailey Hutchison Convention Center Dallas , the Smart Healthcare Pavilion brought together 10 Taiwanese hospitals and health-tech companies working to address this challenge.

Organized by the International Trade Administration (TITA) and the Ministry of Economic Affairs (MOEA), and implemented by TAITRA Global (Taiwan External Trade Development Council), the pavilion showcased solutions ranging from AI-assisted diagnostics and chronic disease management to remote patient monitoring, elder care, and rehabilitation robotics.

Some key highlights included Health2Sync 智抗糖, which helps patients and healthcare providers manage chronic conditions between appointments; Taichung Veterans General Hospital and Chang Gung Memorial Hospital, which are advancing AI applications developed through clinical practice; and Onyx Healthcare and VitalSigns Oy Technology, which are bringing smart monitoring solutions into healthcare settings.

Companies such as FREE Bionics Taiwan, Open Shoulder, GuiderCare, Huijia Health Life Technology Co., Ltd., and HUKUI Biotechnology also demonstrated how Taiwan combines engineering, software, medical expertise, and manufacturing to address real healthcare needs.

During the Expo, TAITRA Chairman James C. F. Huang emphasized the importance of U.S.–Taiwan industrial collaboration, describing the partnership as “co-innovation in action.”

10/13/2026

At BioJapan 2026, HanchorBio Inc. 漢康生技股份有限公司 turned scientific progress into new global partnership opportunities. 🇯🇵

In an exclusive interview with GeneOnline, Henry Ye, Associate BD Director, YU-JIUN (Archer) HUNG, Ph.D., Investor Relations Director, and I-Yin Chen, Ph.D., Senior Director of Discovery Research, shared how HanchorBio plans to build value across its oncology and autoimmune programs.

Through its Fc-Based Designer Biologics (FBDB™) platform, HanchorBio is advancing four programs designed to address multiple disease pathways. Its lead candidate, HCB101, is progressing through clinical development, while HCB301, HCB303, and HCB206 open additional opportunities in cancer and autoimmune diseases.

The company is also exploring co-discovery partnerships that could generate revenue as early as 2027, while building clinical evidence to support future global licensing agreements—including Japan.

As Henry Ye emphasized, the goal is to strengthen each program with meaningful data before entering global licensing discussions. Meanwhile, Archer Hung highlighted how clinical progress supports both partnership opportunities and the company’s long-term growth, and I-Yin Chen underscored the value of combining complementary technologies to accelerate drug development.

10/09/2026

As BioJapan 2026 wraps up in Yokohama, the GeneOnline team visited booths and connected with organizations working to advance healthcare innovation, drug discovery, and the development of next-generation therapies.

The team visited Japan’s Ministry of Health, Labour and Welfare (MHLW) and learned more about the Japan Healthcare Venture Summit 2026 (JHVS), which creates opportunities for healthcare and biotech ventures to present their innovations, connect with pharmaceutical companies, investors, and research institutions, and explore pathways to commercialization. The summit supports the development of Japan’s medical innovation ecosystem, with a focus on bringing promising research closer to practical applications in pharmaceuticals, medical devices, and regenerative medicine. Its venture pitches and networking opportunities also help connect emerging technologies with the expertise and partnerships needed to advance them.

The GeneOnline team also visited Shonan Health Innovation Park (Shonan iPark), a life sciences research and innovation hub established from TakedaPharmaceutical Nordics AB’s research facility. Shonan iPark brings together pharmaceutical companies, biotech startups, academia, and other organizations to accelerate research and translate scientific discoveries into new healthcare solutions. Its development priorities include next-generation therapies such as regenerative medicine, cell and gene therapies, nucleic acid medicines, and mRNA-based drug discovery, supported by plans for research infrastructure, cell processing facilities, and collaboration with clinical research partners.

10/09/2026

As BioJapan 2026 comes to a close, the GeneOnline team visited booths across the exhibition to connect with organizations advancing biotechnology, healthcare innovation, and international collaboration. From Japan’s growing life sciences ecosystem to Spain’s biotech innovators, the event highlighted how research, technology, and partnerships are helping move new ideas toward real-world applications.

At KENTO — Northern Osaka Health and Biomedical Innovation Town (NohBIT), we explored an innovation hub that brings together research institutions, healthcare organizations, companies, and the community. KENTO promotes collaboration between industry and academia, while creating opportunities to test health-related technologies, develop new products and services, and support healthier lifestyles.

The team also visited the Biotech from Spain Pavilion, which showcased Spanish life sciences organizations working across areas such as biotechnology, therapeutics, diagnostics, and research services. These connections demonstrate the value of bringing diverse expertise together to advance biomedical innovation.

Our visit also included the Union of Kansai Governments, representing a region with a strong life sciences ecosystem and active collaboration among universities, research centers, businesses, and public institutions. Kansai continues to build opportunities in biotechnology, healthcare, and regenerative medicine, making international partnerships an important part of its innovation strategy. BioJapan 2026 provided a valuable opportunity to discover emerging developments, exchange perspectives, and strengthen connections across the global life sciences community.

10/09/2026

Japan continues to strengthen its regenerative medicine, cell therapy, and gene therapy (RM/CGT) ecosystem, with CDMOs playing an increasingly important role in turning scientific advances into accessible treatments.

At BioJapan 2026, the Forum for Innovative Regenerative Medicine (FIRM) organized the session “The Current Landscape of the CDMO Ecosystem Driving the Industrialization of Regenerative Medicine, Cell Therapy, and Gene Therapy in Japan.”

The session brought together perspectives from government, AMED, and domestic and international CDMOs to examine the challenges of scaling RM/CGT innovation. Discussions focused on early development decisions, CMC and quality requirements, GMP manufacturing, regulatory strategy, technology transfer, and commercial supply. Speakers also explored how Japan can strengthen domestic manufacturing capabilities, build collaboration across the industry, and apply international experience to accelerate the development of advanced therapies.

With contributions from Mr. Koichi Nakao of Takara Bio Inc., Mr. Yosh*taka Yamamuro of Japan’s Ministry of Economy, Trade and Industry, Dr. Monika Pema, Ph.D of AGC Biologics, Mr. Katsuhito Hashizume of Takara Bio Inc., Mr. Kazuto Yamada of Japan Tissue Engineering Co., Ltd., and Mr. Hirokazu Shimoda of Japan Agency for Medical Research and Development , the panel highlighted the importance of collaboration in building a competitive RM/CGT ecosystem. Strengthening these partnerships will help advance the industrialization of regenerative medicine and bring innovative therapies to patients in Japan and worldwide.

10/09/2026

Women entrepreneurs are driving innovation across life sciences, biotechnology, healthcare, and sustainability. At BioJapan 2026, the Women Entrepreneurship Pitch Session brought together founders, researchers, and industry leaders to discuss the challenges and opportunities involved in scaling women-led businesses globally.

The session featured pitches from Dr. Ayuko Hoshino of The University of Tokyo, Lucy Dain-Williams of Tera Mira, Associate Professor Teruyo Kato of Nagoya University, Dr. Magdalene Yan Yoong Ho, PhD of Traxion Biotech, Moana Kitamura of FLOATMEAL, Sophie Richter of aiKnit, Dr. Motoko Maekawa of Tohoku University, Professor Yuriko Osakabe of Institute of Science Tokyo (Science Tokyo), Louise Lenborg Skajem of Resting Reef, and Rojeanne Stoffer of Arcus Dental. Their presentations covered innovations ranging from regenerative wound care and rehabilitation technology to alternative nutrition, genetic engineering, and diagnostic support. The special panel also explored key strategies for helping women entrepreneurs expand internationally.

Moderated by Masaru Nagura, CEO of Founders Nation, the session created space for founders, researchers, investors, and industry representatives to exchange ideas and showcase emerging technologies. It was a pleasure listening to the speakers, moderators, and participants contributing to the discussion on empowering women entrepreneurs and advancing innovation across the global life sciences ecosystem.

10/09/2026

As the global biopharma landscape pivots towards complex modalities and streamlined commercialization, the GeneOnline team is on the ground at CPHI Milan 2026 exploring the most impactful B2B partnerships.

Today, we stopped by the EirGenix, Inc. booth for an exclusive inside look at their expanding global footprint. The company’s exhibition wall immediately highlights their scale, showcasing a growing total capacity of 29.6 kL, over 100+ products in development, and prestigious regulatory approvals from 5 major global agencies (US FDA, EU EMA, Japan PMDA, Taiwan TFDA, Australia TGA). Their displayed end-to-end CDMO solutions cover everything from mono/bi-specific antibodies to ADCs and pDNA.

To understand the strategy behind the numbers, we sat down for an exclusive on-site interview with EirGenix's Business Development leadership: Leon Huang, Brendan Lee, and Albert Chung-Huan Lin.

Here are the core insights they shared regarding the future of biomanufacturing:
🔹The "Dual-Engine" Advantage With their newly launched Zhubei Microbial Facility operating alongside their established Mammalian (CHO) infrastructure, EirGenix now offers manufacturing up to a 1,500L microbial scale.

🔹By offering access to their proprietary cell line platforms, ADC integration expertise, and the novel Hyalgenix (hyaluronidase) subcutaneous delivery tech, EirGenix is helping international partners share risks and build highly competitive IP portfolios.

🔹For agile biotech startups, EirGenix provides cost-effective, fast-track pathways to IND; for global pharma giants, they deliver the proven, commercial-scale CMC excellence required to seamlessly pass stringent global audits.

10/09/2026

The CDMO industry continues to evolve as pharmaceutical companies seek greater manufacturing capacity, specialized capabilities, and more resilient supply chains.

At CPHI Milan 2026, Ayan Deb, Principal, Strategy Consulting at IQVIA, presented “Navigating the CDMO Landscape: Market Trends, Emerging Opportunities, and the China Impact.” The session explored the market forces shaping the global CDMO industry, including growth in sterile fill-finish manufacturing, rising demand for biologics and GLP-1 therapies, and the strategic implications of China’s growing role in global innovation. It also highlighted key challenges around supply chain resilience, regulatory compliance, capacity planning, and competition.

As demand for complex therapies grows, CDMOs have opportunities to strengthen their market position through capacity expansion, downstream integration, and investments in specialized drug-delivery technologies. Understanding these shifts will be essential for companies making strategic decisions in an increasingly competitive market.

The session was sponsored by Thermo Fisher Scientific during CPHI Milan 2026.

10/09/2026

At CPHI Milan 2026, industry leaders came together for the panel “CDMO Strategic Inflection Point: From Capacity Provider to Innovation Architect,” sponsored by Thermo Fisher Scientific. The discussion explored how contract development and manufacturing organizations (CDMOs) can move beyond providing manufacturing capacity to become strategic partners that support innovation, strengthen collaboration, and help pharmaceutical companies navigate increasingly complex development and manufacturing needs.

Moderated by Bernardo Estupian, CDMO Advisor ™, the panel featured Lauren Schulte Kjeldsen, Evonik Industries ; Eduardo Jule, PhD, Lupin Manufacturing Solutions; Ravi Rai, Curia Global; Hubert Scholze, Rezon Bio ; and Allyson Costa, Lonza.

As the pharmaceutical industry continues to evolve, CDMOs have an opportunity to create greater value by combining technical expertise, commercial strategy, and innovative manufacturing solutions. The panel highlighted the importance of rethinking the CDMO role and building partnerships that go beyond production to help advance pharmaceutical development.

GeneOnline

10/14/2026

10/14/2026

10/13/2026

10/09/2026

10/09/2026

10/09/2026

10/09/2026

10/09/2026

10/09/2026

10/09/2026

Address

Telephone

Website

Alerts

Contact The Business

Shortcuts

Share

Listing takedown request